No Picture
InMed Pharmaceuticals Inc.

InMed Files Patent Application for INM-085 Glaucoma Program

VANCOUVER, May 14, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high […]

No Picture
InMed Pharmaceuticals Inc.

InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

VANCOUVER, May 11, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases […]

No Picture
InMed Pharmaceuticals Inc.

InMed Rings the Opening Bell at the Toronto Stock Exchange

VANCOUVER, April 17, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases […]

No Picture
InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

Trading on the TSX will commence March 26, 2018 VANCOUVER, March 23, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced that […]

No Picture
InMed Pharmaceuticals Inc.

InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development

VANCOUVER, March 13, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the appointment of Eric Hsu, Ph.D., as […]

No Picture
InMed Pharmaceuticals Inc.

InMed to Present at 30th Annual ROTH Capital Conference

VANCOUVER, March 12, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment […]

No Picture
InMed Pharmaceuticals Inc.

InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed’s Fully Integrated, Cannabinoid-based Business Model CSE: IN OTCQB: IMLFF VANCOUVER, March 6, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: […]

No Picture
InMed Pharmaceuticals Inc.

InMed Receives Conditional Approval to List on the Toronto Stock Exchange

VANCOUVER, March 2, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the […]